================================================================================
FILE: CIMB_detailed_PLS_READ.pdf
================================================================================
Total pages: 16

--- Page 1 ---
Problem Statement 3 [Track 1]:
Corrected Integrated Mass Balance (CIMB):
A Mechanistic, Statistical & Regulatory
Framework
Aarav Singla
January 2026
Abstract
This proposal introduces theCorrected Integrated Mass Balance (CIMB)
method, a comprehensive approach that addresses critical limitations in existing
mass balance calculation methods for forced degradation studies. The CIMB method
integrates multiple correction factors including relative response factors (RRF),
molecular weight adjustments, analytical uncertainty quantification, and degrada-
tion pathway considerations to provide the most accurate mass balance assessment
available. By transforming mass balance from a binary pass/fail metric into a quan-
titative risk assessment tool with confidence intervals, CIMB enables more informed
decision-making about analytical method adequacy while maintaining regulatory
compliance.
Contents
1 Phase 1: Critical Gap Analysis of Conventional Mass Balance Methods 3
1.1 Background and Importance . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.2 Fundamental Flaws in Existing Methods . . . . . . . . . . . . . . . . . . . 3
1.3 Key Challenges Identified from Literature . . . . . . . . . . . . . . . . . . 4
1.4 Failure Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1

--- Page 2 ---
2 Phase 2: Proposed Innovation û CIMB Framework 5
2.1 The Corrected Integrated Mass Balance (CIMB) Method . . . . . . . . . . 5
2.2 Statistical Confidence Interval . . . . . . . . . . . . . . . . . . . . . . . . . 5
2.3 Component Definitions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
2.4 Key Innovation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
3 CIMB Calculation Workflow 7
3.1 Step 1: Determine Initial API Assay . . . . . . . . . . . . . . . . . . . . . 7
3.2 Step 2: Measure Stressed Sample API and Degradants . . . . . . . . . . . 7
3.3 Step 3: Determine RRF for Each Degradant . . . . . . . . . . . . . . . . . 7
3.4 Step 4: Calculate Molecular Weight Correction . . . . . . . . . . . . . . . . 7
3.5 Step 5: Apply Stoichiometric Corrections . . . . . . . . . . . . . . . . . . . 8
3.6 Step 6: Calculate CIMB Point Estimate . . . . . . . . . . . . . . . . . . . 8
3.7 Step 7: Calculate Confidence Interval . . . . . . . . . . . . . . . . . . . . . 8
4 Phase 3: Computational Validation 8
4.1 Simulation Parameters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
4.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
5 Phase 4: Risk-Based Regulatory Framework 10
5.1 Backward Compatibility . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
6 Worked Example 11
6.1 Scenario . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
6.2 Data Collection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
6.3 Calculation Steps . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
6.4 Result Interpretation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
6.5 Comparison to Traditional Methods . . . . . . . . . . . . . . . . . . . . . . 12
7 Implementation Guidance 13
7.1 When to Apply Each Correction . . . . . . . . . . . . . . . . . . . . . . . . 13
7.2 Documentation Requirements . . . . . . . . . . . . . . . . . . . . . . . .

--- Page 3 ---
8 Key Advantages of CIMB Method 13
9 Conclusion 14
PROTOTYPE DEMO: Please do CLICK BELOW
Launch Presentation
1 Phase 1: Critical Gap Analysis of Conventional
Mass Balance Methods
1.1 Background and Importance
Mass balance calculations are fundamental to forced degradation studies, serving as a
critical quality control metric that demonstrates:
òCompleteness of analytical methods in detecting all degradation products
òUnderstanding of degradation pathways and mechanisms
òStability-indicating nature of analytical procedures
òRegulatory compliance with ICH Q1A(R2) guidelines [1]
Regulatory Expectation:The ICH Q1A(R2) guideline defines mass balance asôthe
process of adding together the assay value and levels of degradation products to see how
closely these add up to 100% of the initial value, with due consideration of the margin of
analytical error.öThe industry standard acceptance range is typically 97û104%, though
recent literature suggests refinements may be needed based on analytical variability and
degradation complexity [2].
1.2 Fundamental Flaws in Existing Methods
Conventional Mass Balance methods (SMB, AMB, RMB) assume:
òIdentical detector response for all compounds (RRF = 1)
òEqual molecular weight of degradants and parent API
3

--- Page 4 ---
Error: 'charmap' codec can't encode character '\u0338' in position 350: character maps to <undefined>

================================================================================
FILE: LK-IMB_detailed_PLS_READ.pdf
================================================================================
Total pages: 16

--- Page 1 ---
Problem Statement 3 [ Track 1 ]:
Mass Balance Optimization & Theoretical
Validation
by Aarav Singla
Contents
1 Critical Gap Analysis of Conventional Methods 3
1.1 Three Fundamental Failures . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.2 Industry Impact: Quantifying the Problem . . . . . . . . . . . . . . . . . . 3
2 The LK-IMB Framework: Correcting Systematic Bias 4
2.1 The Lukulay-K¿ orner Integrated Equation (LK-IMB) . . . . . . . . . . . . . 4
2.2 Mathematical Rigor: Error Propagation Analysis . . . . . . . . . . . . . . 4
2.3 Edge Case Handling: Practical Robustness . . . . . . . . . . . . . . . . . . 5
2.4 Adaptive Decision Matrix . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
2.5 ICH Compliance Checklist . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
3 Computational Validation 6
4 Real-Time Deficit Diagnosis System (RDDS) 6
4.1 The Problem: Trial-and-Error Wastes 3-7 Days . . . . . . . . . . . . . . . 6
4.2 Impact: 87% Accuracy, 60% Faster Investigations . . . . . . . . . . . . . . 7
4.3 Future Enhancement: Machine Learning Integration . . . . . . . . . . . . . 7
5 Confidence Index: Preventing False Investigations 7
5.1 The Formula . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
5.2 Decision Thresholds . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
5.3 Statistical Rigor: Receiver Operating Characteristic (ROC) Analysis . . . . 8
1

--- Page 2 ---
5.4 Impact:$450K Annual Savings . . . . . . . . . . . . . . . . . . . . . . . . 8
6 Regulatory Defensibility 9
6.1 Mock FDA 483 Observation . . . . . . . . . . . . . . . . . . . . . . . . . . 9
6.2 How LK-IMB Prevents This . . . . . . . . . . . . . . . . . . . . . . . . . . 9
6.3 Industry Precedents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
7 Cost-Benefit Analysis 9
7.1 Total ROI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
7.2 Sensitivity Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
7.3 Beyond Direct Savings: Strategic Competitive Advantage . . . . . . . . . . 10
7.4 Comparison to Alternative Approaches . . . . . . . . . . . . . . . . . . . . 10
8 Deliverables & Implementation 11
8.1 Heat Map: Method Performance . . . . . . . . . . . . . . . . . . . . . . . . 11
8.2 Decision Tree . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
8.3 Excel & Web App Prototypes . . . . . . . . . . . . . . . . . . . . . . . . . 12
8.4 12-Month Rollout . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
8.5 Risk Mitigation & Quality Assurance . . . . . . . . . . . . . . . . . . . . . 12
8.6 Quality Metrics & KPIs . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
9 Conclusion 13
9.1 What We Delivered . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
9.2 Why This Wins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
9.3 Innovation Scorecard . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
9.4 Dissemination & Knowledge Transfer . . . . . . . . . . . . . . . . . . . . . 14
9.5 Competitive Advantage: Why Novartis Should Implement First . . . . . . 15
PROTOTYPE DEMO: Please do CLICK BELOW
Launch Presentation
2

--- Page 3 ---
Error: 'charmap' codec can't encode character '\u2192' in position 414: character maps to <undefined>

================================================================================
FILE: Combined_Report_PLS_READ.pdf
================================================================================
Total pages: 29

--- Page 1 ---
Problem Statement 3 [ Track 1 ]:
Mass Balance Optimization & Theoretical
Validation
1.CIMB Framework
2.LK-IMB Framework
by Aarav Singla
* LK-IMB Framework starts from Section 10
PLEASE DO READ BOTH SOLUTIONS
Contents
1 Phase 1: Critical Gap Analysis of Conventional Mass Balance Methods 4
1.1 Background and Importance . . . . . . . . . . . . . . . . . . . . . . . . . . 4
1.2 Fundamental Flaws in Existing Methods . . . . . . . . . . . . . . . . . . . 4
1.3 Key Challenges Identified from Literature . . . . . . . . . . . . . . . . . . 5
1.4 Failure Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
2 Phase 2: Proposed Innovation û CIMB Framework 6
2.1 The Corrected Integrated Mass Balance (CIMB) Method . . . . . . . . . . 6
2.2 Statistical Confidence Interval . . . . . . . . . . . . . . . . . . . . . . . . . 6
2.3 Component Definitions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
2.4 Key Innovation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
3 CIMB Calculation Workflow 8
3.1 Step 1: Determine Initial API Assay . . . . . . . . . . . . . . . . . . . . . 8
3.2 Step 2: Measure Stressed Sample API and Degradants . . . . . . . . . . . 8
1

--- Page 2 ---
3.3 Step 3: Determine RRF for Each Degradant . . . . . . . . . . . . . . . . . 8
3.4 Step 4: Calculate Molecular Weight Correction . . . . . . . . . . . . . . . . 8
3.5 Step 5: Apply Stoichiometric Corrections . . . . . . . . . . . . . . . . . . . 9
3.6 Step 6: Calculate CIMB Point Estimate . . . . . . . . . . . . . . . . . . . 9
3.7 Step 7: Calculate Confidence Interval . . . . . . . . . . . . . . . . . . . . . 9
4 Phase 3: Computational Validation 9
4.1 Simulation Parameters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
4.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
5 Phase 4: Risk-Based Regulatory Framework 11
5.1 Backward Compatibility . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
6 Worked Example 11
6.1 Scenario . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
6.2 Data Collection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
6.3 Calculation Steps . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
6.4 Result Interpretation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
6.5 Comparison to Traditional Methods . . . . . . . . . . . . . . . . . . . . . . 13
7 Implementation Guidance 13
7.1 When to Apply Each Correction . . . . . . . . . . . . . . . . . . . . . . . . 14
7.2 Documentation Requirements . . . . . . . . . . . . . . . . . . . . . . . . . 14
8 Key Advantages of CIMB Method 14
9 Conclusion 15
10 The LK-IMB Framework: Correcting Systematic Bias 17
10.1 The Lukulay-K¿ orner Integrated Equation (LK-IMB) . . . . . . . . . . . . . 17
10.2 Mathematical Rigor: Error Propagation Analysis . . . . . . . . . . . . . . 17
10.3 Edge Case Handling: Practical Robustness . . . . . . . . . . . . . . . . . . 18
10.4 Adaptive Decision Matrix . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
10.5 ICH Compliance Checklist . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
11 Computational Validation 18
2

--- Page 3 ---
12 Real-Time Deficit Diagnosis System (RDDS) 19
12.1 The Problem: Trial-and-Error Wastes 3-7 Days . . . . . . . . . . . . . . . 19
12.2 Impact: 87% Accuracy, 60% Faster Investigations . . . . . . . . . . . . . . 20
12.3 Future Enhancement: Machine Learning Integration . . . . . . . . . . . . . 20
13 Confidence Index: Preventing False Investigations 20
13.1 The Formula . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
13.2 Decision Thresholds . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
13.3 Statistical Rigor: Receiver Operating Characteristic (ROC) Analysis . . . . 21
13.4 Impact:$450K Annual Savings . . . . . . . . . . . . . . . . . . . . . . . . 21
14 Regulatory Defensibility 21
14.1 Mock FDA 483 Observation . . . . . . . . . . . . . . . . . . . . . . . . . . 21
14.2 How LK-IMB Prevents This . . . . . . . . . . . . . . . . . . . . . . . . . . 22
14.3 Industry Precedents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
15 Cost-Benefit Analysis 22
15.1 Total ROI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
15.2 Sensitivity Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
15.3 Beyond Direct Savings: Strategic Competitive Advantage . . . . . . . . . . 22
15.4 Comparison to Alternative Approaches . . . . . . . . . . . . . . . . . . . . 23
16 Deliverables & Implementation 23
16.1 Heat Map: Method Performance . . . . . . . . . . . . . . . . . . . . . . . . 24
16.2 Decision Tree . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
16.3 Excel & Web App Prototypes . . . . . . . . . . . . . . . . . . . . . . . . . 24
16.4 12-Month Rollout . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
16.5 Risk Mitigation & Quality Assurance . . . . . . . . . . . . . . . . . . . . . 25
16.6 Quality Metrics & KPIs . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
17 Conclusion 26
17.1 What We Delivered . . . . . . . . . . . . . . . . 

--- Page 4 ---
17.4 Dissemination & Knowledge Transfer . . . . . . . . . . . . . . . . . . . . . 27
17.5 Competitive Advantage: Why Novartis Should Implement First . . . . . . 28
1 Phase 1: Critical Gap Analysis of Conventional
Mass Balance Methods
1.1 Background and Importance
Mass balance calculations are fundamental to forced degradation studies, serving as a
critical quality control metric that demonstrates:
òCompleteness of analytical methods in detecting all degradation products
òUnderstanding of degradation pathways and mechanisms
òStability-indicating nature of analytical procedures
òRegulatory compliance with ICH Q1A(R2) guidelines [4]
Regulatory Expectation:The ICH Q1A(R2) guideline defines mass balance asôthe
process of adding together the assay value and levels of degradation products to see how
closely these add up to 100% of the initial value, with due consideration of the margin of
analytical error.öThe industry standard acceptance range is typically 97û104%, though
recent literature suggests refinements may be needed based on analytical variability and
degradation complexity [2].
1.2 Fundamental Flaws in Existing Methods
Conventional Mass Balance methods (SMB, AMB, RMB) assume:
òIdentical detector response for all compounds (RRF = 1)
òEqual molecular weight of degradants and parent API
òNo analytical uncertainty quantification
òNo stoichiometric corrections for reaction pathways
These assumptions violate the conservation of mass and statistical inference under real
degradation pathways [1, 2].
4

--- Page 5 ---
Error: 'charmap' codec can't encode character '\u0338' in position 134: character maps to <undefined>

================================================================================
FILE: novartis_3_1_slides_ppt.pdf
================================================================================
Total pages: 37

--- Page 1 ---
From Fractured  to Functional: 
Reinventing  Mass Balance  in Pharma
Team:  aarav.singla
Novartis  NEST  Hackathon  2026
February  2026
*Prototype Video in the last slide

--- Page 2 ---
The Pharmaceutical  Problem  Nobody  Talks About
Mass balance  (MB) in forced  degradation  is foundational  ù yet fails 
far too often.
Investigations  waste time, delay releases,  and cost millions  when MB 
doesnÆt  add up.
Ironically,  we rely on methods  that ignore  real chemistry.
Metaphor:  öMass  balance  is like pharmaÆs  bad Wi-Fi ù flaky, unreliable, 
and everyoneÆs  blaming  the router  (detector).ö
on 2026) Team:  aarav.singla  (Novartis  NEST  Hackath CIMB++  Final Presentation February  2026 2 / 36

--- Page 3 ---
The Hidden  Cost of Unreliable  Mass Balance
Key impacts  of MB failures:
30û45 days
typical  duration  of an OOS
investigation
$25Kû$55K
projected average  cost per
deviation  investigation
$1û2M
projected  additional loss if
batch must be reworked  or 
scrappedThe root cause:
Using  OLD  Math 
for Modern 
Chemistry
ôThe  problem  isnÆt the science.
ItÆs the math.ö
Sources:  Industry  data ,ICH 
Q1A(R2),Blessy  et al., Journal  of 
Pharmaceutical  Analysis,  2014,FDA 
stability  guidance
on 2026) Team:  aarav.singla  (Novartis  NEST  Hackath CIMB++  Final Presentation February  2026 3 / 36

--- Page 4 ---
Real-World  Consequences  of Poor Mass Balance
Regulatory  Risk:  ICH Q1A(R2)  expects  100% mass balance ù 
missing  10% can trigger  full investigations.
Time  Lost:  Investigations  can delay batch release  by 2û6 weeks. 
Costly  Detours:  $100k+  spent on root cause analysis,  stress study 
repeats, and justifications.
Reputation:  MB issues  create audit flags and internal  friction 
between  R&D, QA, and manufacturing.
on Team:  aarav.singla  (Novartis  NEST  Hackath CIMB++  Final Presentation February  2026 4 / 36

--- Page 5 ---
Why Existing  MB Methods  Fail
SMB  û Simple  Mass  Balance : Based  only on purity  and total 
degradants . Ignores  UV response  factors  and molecular  weights . 
Over-simplified .
AMB  û Absolute  Mass  Balance : Measures  all peaks  by area. 
Misses  UV-invisible  degradants . No stoichiometric  awareness .
RMB  û Relative  Mass  Balance : Assumes  equal detectability . 
Overreacts  to low-degradation  scenarios .
on 2026) Team:  aarav.singla  (Novartis  NEST  Hackath CIMB++  Final Presentation February  2026 5 / 36

--- Page 6 ---
Error: 'charmap' codec can't encode character '\u03bb' in position 209: character maps to <undefined>

